Contributions of imprecision in PET‐MRI rigid registration to imprecision in amyloid PET SUVR measurements

Quantitative measurement of β‐amyloid from amyloid PET scans typically relies on localizing target and reference regions by image registration to MRI. In this work, we present a series of simulations where 50 small random perturbations of starting location and orientation were applied to each subject's PET scan, and rigid registration using spm_coreg was performed between each perturbed PET scan and its corresponding MRI. We then measured variation in the output PET‐MRI registrations and how this variation affected the resulting SUVR measurements. We performed these experiments using scans of 1196 participants, half using 18F florbetapir and half using 11C PiB. From these experiments, we measured the magnitude of the imprecision in the rigid registration steps used to localize measurement regions, and how this contributes to the overall imprecision in SUVR measurements. Unexpectedly, we found for both tracers that the imprecision in these measurements depends on the degree of amyloid tracer uptake, and thus also indirectly on Alzheimer's disease clinical status. We then examined common choices of reference regions, and we show that SUVR measurements using supratentorial white matter references are relatively resistant to this source of error. We also show that the use of partial volume correction further magnifies the effects of registration imprecision on SUVR measurements. Together, these results suggest that this rigid registration step is an attractive target for future work in improving measurement techniques. Hum Brain Mapp 38:3323–3336, 2017. © 2017 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc.

[1]  R L Wahl,et al.  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.

[2]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[3]  Jeffrey A. Fessler,et al.  Reducing between scanner differences in multi-center PET studies , 2009, NeuroImage.

[4]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[5]  John Seibyl,et al.  Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.

[6]  Kengo Ito,et al.  Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study , 2011, Annals of Nuclear Medicine.

[7]  Sébastien Ourselin,et al.  PIB-PET SEGMENTATION FOR AUTOMATIC SUVR NORMALISATION WITHOUT MR INFORMATION , 2007, 2007 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro.

[8]  B. Thomas Improved brain PET quantification using partial volume correction techniques , 2012 .

[9]  Mark A. Mintun,et al.  A Semiautomated Method for Quantification of F 18 Florbetapir PET Images , 2015, The Journal of Nuclear Medicine.

[10]  William J. Jagust,et al.  Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.

[11]  J. Tukey,et al.  Variations of Box Plots , 1978 .

[12]  Christopher C Rowe,et al.  Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.

[13]  Clifford R. Jack,et al.  Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE , 2017, NeuroImage.

[14]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[15]  Christer Halldin,et al.  Evaluation of Two Automated Methods for PET Region of Interest Analysis , 2014, Neuroinformatics.

[16]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[17]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[18]  E G Tangalos,et al.  Prevalence of mild cognitive impairment is higher in men , 2010, Neurology.

[19]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[20]  J O Rinne,et al.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls , 2009, Neurology.

[21]  Arthur W. Toga,et al.  Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: Application to normal elderly and Alzheimer's disease participants , 2009, NeuroImage.

[22]  Brian B. Avants,et al.  Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain , 2008, Medical Image Anal..

[23]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[24]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[25]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Yun Zhou,et al.  Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease , 2007, NeuroImage.

[27]  Owen Carmichael,et al.  Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[28]  V. Pankratz,et al.  The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.

[29]  Jochen Herms,et al.  Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET , 2014, NeuroImage.

[30]  Daniel Bandy,et al.  Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region , 2015, The Journal of Nuclear Medicine.

[31]  Olivier Salvado,et al.  MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET , 2014, PloS one.

[32]  Olivier Salvado,et al.  MR-Less High Dimensional Spatial Normalization of 11C PiB PET Images on a Population of Elderly, Mild Cognitive Impaired and Alzheimer Disease Patients , 2008, MICCAI.

[33]  C. Jack,et al.  A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity , 2016, NeuroImage: Clinical.

[34]  Felix Carbonell,et al.  Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images , 2015, The Journal of Nuclear Medicine.

[35]  Robert A. Dean,et al.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.

[36]  Lennart Thurfjell,et al.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.

[37]  H. Mayberg,et al.  Correction of PET Data for Partial Volume Effects in Human Cerebral Cortex by MR Imaging , 1990, Journal of computer assisted tomography.

[38]  C. Jack,et al.  Comparison of 18F-FDG and PiB PET in Cognitive Impairment , 2009, Journal of Nuclear Medicine.

[39]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[40]  P. Vemuri,et al.  Brain β-amyloid load approaches a plateau , 2013, Neurology.

[41]  R. Boellaard,et al.  Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  Keith A. Johnson,et al.  Partial volume correction in quantitative amyloid imaging , 2015, NeuroImage.

[43]  John Seibyl,et al.  Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans , 2016, The Journal of Nuclear Medicine.

[44]  Paul Edison,et al.  Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET , 2013, NeuroImage.